Search Results

The ADVIA Centaur® Insulin (IRI) Master Curve Material (MCM) is for in vitro diagnostic use in the verification of calibration and reportable range of the ADVIA Centaur® Insuin assay.

The ADVIA Centaur® Insulin (IRI) Calibrator is for in vitro diagnostic use in calibrating the ADVIA Centaur® systems Insulin assays.

ADVIA Centaur® Insulin (IRI) Master Curve Material is a set of ten vials of material containing various levels of insulin in buffered saline with casein, potassium thiocyanate (3.89%), sodium azide (

The provided text describes modifications to the "ADVIA Centaur® Insulin (IRI) Master Curve Material (MCM)" and "ADVIA Centaur® Insulin (IRI) Calibrator" and outlines the studies conducted to demonstrate their substantial equivalence to predicate devices.

Here's an analysis of the acceptance criteria and the study information, extracting what is available:

1. Table of Acceptance Criteria and Reported Device Performance:

The document doesn't explicitly state quantitative acceptance criteria in a table format with corresponding performance metrics for the modified devices. Instead, it states that "Verification testing was conducted and results show that the modified devices meet pre-determined acceptance criteria." and that a "method comparison study demonstrates that human clinical sample results are equivalent with both calibrators (modified and unmodified)."

However, based on the context, the implicit acceptance criteria and reported performance would be:

Ask a specific question about this device

The ADVIA Centaur® Follicle Stimulating Hormone (FSH) Master Curve Material is for in vitro diagnostic use in the verification of calibration and reportable range of the ADVIA Centaur FSH assay.
The ADVIA Centaur® Free thyroxine (FT4) Master Curve Material is for in vitro diagnostic use in the verification of calibration and reportable range of the ADVIA Centaur FT4 assay.
The ADVIA Centaur® Thyroxine (T4) Master Curve Material is for in vitro diagnostic use in the verification of calibration and reportable range of the ADVIA Centaur T4 assay.
The ADVIA Centaur® Triiodothyronine (T3) Master Curve Material is for in vitro diagnostic use in the verification of calibration and reportable range of the ADVIA Centaur T3 assay.

ADVIA Centaur® FSH Master Curve Material is an in vitro diagnostic product containing various levels of follicle stimulating hormone spiked in lyophilized equine serum with sodium azide (0.1% after reconstitution) and preservatives. Each set contains eight levels (MCM1–8); with a reconstituted volume of 1.0 mL/vial per level. MCM1contains no analyte. The MCMs assigned values are lot-specific of target values: 0.00, 1.50, 4.50, 12.0, 30.0, 62.5, 130, 225 mIU/mL.
ADVIA Centaur® FT4 Master Curve Material is an in vitro diagnostic product containing various levels of thyroxine in human plasma with sodium azide. Each set contains seven levels; with a reconstituted volume of 1.0 mL/vial per level. MCM1 contains no analyte. The FT4 MCMs assigned values are lot-specific of target values: 0.00, 2.00, 5.00, 10.0, 15.0, 22.0, and 35.0 µg/dL which corresponds to FT4 values of 0.00, 0.42, 0.80, 1.70, 3.0, 5.6, and 13.5 ng/dL.
ADVIA Centaur® T4 Master Curve Material is an in vitro diagnostic product containing various levels of levothyroxine in human plasma with sodium azide and preservatives. Each set contains six levels; with a reconstituted volume of 1.0 mL/vial per level. MCM1 contains no analyte. The T4 MCMs assigned values are lot-specific of target values: 0.00, 2.50, 5.00, 10.0, 15.0. and 35.0 µg/dL.
ADVIA Centaur® T3 Master Curve Material is an in vitro diagnostic product containing various levels of liothyronine in human plasma with sodium azide and preservatives. Each se contains seven levels; with a reconstituted volume of 1.0 mL/vial per level. MCM1 contains no analyte. The T3 MCMs assigned values are lot-specific of target values: 0.00, 0.42, 0.69, 1.11, 1.65, 3.87, and 7.00 ng/mL.

The provided document describes the Siemens Healthcare Diagnostics ADVIA Centaur® Master Curve Materials (MCM) for Follicle Stimulating Hormone (FSH), Free Thyroxine (FT4), Thyroxine (T4), and Triiodothyronine (T3). These devices are quality control materials used for verification of calibration and reportable ranges of their respective ADVIA Centaur assays. The information is presented as a 510(k) Summary, which focuses on demonstrating substantial equivalence to predicate devices, rather than a detailed report of a clinical study for device performance against specific patient outcomes or diagnostic accuracy.

Here's a breakdown of the requested information based on the provided text, with an emphasis on its applicability to in vitro diagnostic quality control materials rather than typical diagnostic imaging AI studies, which often involve human readers and expert consensus.

1. Table of Acceptance Criteria and Reported Device Performance

The acceptance criteria for these devices are primarily related to stability (shelf-life, open vial, and on-board stability) and value assignment. The reported performance indicates that these criteria were met.

ADVIA Centaur® FSH Master Curve Material

ADVIA Centaur® FT4 Master Curve Material

ADVIA Centaur® T4 Master Curve Material

ADVIA Centaur® T3 Master Curve Material

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

The document describes several non-clinical performance tests, primarily stability studies and value assignment. These are prospective tests conducted by the sponsor (Siemens Healthcare Diagnostics Inc.).

• Stability Studies (Test Set):
  • Real Time/Shelf Life (Unopened): Each MCM (FSH, FT4, T4, T3) was stored unopened at 2-8°C and tested at T=0, 7 months, and 10 or 11 months. Ongoing studies were mentioned at further time points (e.g., 14, 18, 24, 25 months for FSH; 15, 19, 24, 30, 31 months for FT4, T4, T3). The comparison was made against -80°C reference MCMs. No specific number of replicate MCM vials tested at each time point is explicitly stated, other than 'test FSH MCMs were stored'.
  • In-Use Open Vial (Reconstituted): Each MCM (FSH, FT4, T3) was reconstituted, pooled, aliquoted, and stored at 2-8°C. They were tested in 5 replicates per level at T=0, 7, 14, 21, 28, and 29 days (for FSH, T3) or T=0, 7, 14, 21, 28, and 29 days (for FT4). T4 MCM summary did not include open vial stability data details.
  • On-Board Stability: Pooled aliquots of each MCM (FSH, FT4, T3) in sample cups were stored on the ADVIA Centaur system and measured at T=0, 2, 4, and 5 hours. T4 MCM summary did not include on-board stability data details.
• Value Assignment (Test Set):
  • For each new MCM lot, MCM1 (analyte-free) was run in 5 replicates on two separate runs.
  • Other MCM levels (MCM2-8 for FSH, MCM2-7 for FT4/T3, MCM2-6 for T4) were tested using a nested testing run protocol with alternating samples of reference and new MCM, totaling 20 replicates.
  • A performance verification run consisted of 6 replicates of each MCM level.
• Data Provenance: The studies were conducted by Siemens Healthcare Diagnostics Inc., likely in the USA. The data is prospective, generated specifically for this 510(k) submission.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

This type of in vitro diagnostic quality control material does not rely on "expert" interpretation in the same way as, for example, an imaging device. The "ground truth" for these materials is established through a process of:

• Traceability: Standardization to internationally recognized reference materials (e.g., WHO 2nd International Standard for human FSH) or internal standards traceable to official pharmacopeia (USP T4, T3 stock).
• Assigned Values: The values of the MCMs are assigned by the manufacturer based on these traceable standards and validated measurement procedures.
• Internal Protocols: The "sponsor's internal procedural specifications" and "qualified materials and measurement procedures" form the basis for establishing the expected values and ranges.

Therefore, there are no "experts" (like radiologists) establishing ground truth in terms of diagnostic interpretation from patient data. The ground truth is analytical and based on metrological traceability and rigorous laboratory procedures.

4. Adjudication method (e.g., 2+1, 3+1, none) for the test set

Adjudication methods like 2+1 or 3+1 (where multiple experts independently assess and then resolve discrepancies) are not applicable here. These methods are used in scenarios involving subjective expert interpretation, often for imaging or clinical diagnosis. For these quality control materials, "ground truth" and performance are determined through quantitative analytical measurements against established reference values and statistical methods to ensure measurements fall within specified limits.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

MRMC studies are typically performed for diagnostic imaging devices where human readers (e.g., radiologists) interpret cases, sometimes with AI assistance. This document describes in vitro diagnostic quality control materials, not a diagnostic AI device that involves human interpretation of cases. Therefore, no MRMC comparative effectiveness study was performed, and thus no effect size for human reader improvement with AI assistance is mentioned.

6. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done

Yes, the studies described are standalone in the sense that they evaluate the performance of the quality control materials themselves (stability, value assignment) within the ADVIA Centaur assay system, without direct human cognitive input being part of the 'device's' analytical function during testing. The "algorithm" here is the underlying immunoassay technology, and the MCM's performance is tested analytically.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)

The ground truth used for these quality control materials is analytical traceability to recognized international standards (WHO) or national pharmacopeia (USP) for the respective analytes. It also includes reliance on the sponsor's "qualified materials and measurement procedures" and internal procedural specifications for value assignment. This is an objective, quantitative ground truth, not derived from expert consensus, pathology, or outcomes data.

8. The sample size for the training set

The concept of a "training set" is relevant for machine learning algorithms. These devices are chemical/biological reagents designed as quality control materials for immunoassays, not AI algorithms. Therefore, there is no "training set" as understood in machine learning. The manufacturing processes and associated testing are quality control steps, not a machine learning training phase.

9. How the ground truth for the training set was established

As there is no "training set" in the machine learning sense for these devices, this question is not applicable. The establishment of ground truth for the performance evaluation (test set, as discussed in point 7) is through analytical traceability to standards.

Ask a specific question about this device

The ADVIA Centaur® IgE Master Curve Material is for in vitro diagnostic use in the verification of calibration and reportable range of the ADVIA Centaur Total IgE assay.

ADVIA Centaur® IgE Master Curve Material is an in vitro diagnostic product containing various levels of IgE spiked in lyophilized human plasma with sodium azide (0.1%) and preservatives. Each set contains seven levels (MCM1–7); with a reconstituted volume of 1.0 mL/vial per level. MCM1 contains no analyte. The MCMs assigned values are lot-specific of target values: 0.0, 12.5, 40.0, 270, 1000, 1700, and 3150 IU/mL.

This document describes the ADVIA Centaur® IgE Master Curve Material (MCM), a quality control material used for in vitro diagnostic verification of calibration and reportable range of the ADVIA Centaur Total IgE assay. It is not an AI/ML device, and therefore several of the requested sections (e.g., sample size for test/training sets, number/qualifications of experts, adjudication methods, MRMC studies, standalone algorithm performance, data provenance) are not applicable.

Here's a breakdown of the available information:

1. Table of Acceptance Criteria and Reported Device Performance

The device is a quality control material, not a diagnostic test with metrics like sensitivity or specificity. Its performance is measured by its stability and its ability to be correctly value-assigned.

Ask a specific question about this device

The ADVIA Centaur® Prolactin (PRL) Master Curve Material is for in vitro diagnostic use in the verification of calibration and reportable range of the ADVIA Centaur Prolactin assay.
The ADVIA Centaur® Cortisol (COR) Master Curve Material is for in vitro diagnostic use in the verification of calibration and reportable range of the ADVIA Centaur Cortisol assay.

ADVIA Centaur® Prolactin Master Curve Material is an in vitro diagnostic product containing various levels of prolactin spiked in lyophilized equine serum with sodium azide (0.1%) and preservatives including amphotericin B. Each set contains ten levels (MCM1–10); with a reconstituted volume of 1.0 mL per level. MCM1contains no analyte. The MCMs assigned values are lot-specific of target values: 0.00, 2.11, 4.61, 9.21, 26.0, 51.1, 82.9, 113, 161, and 218 ng/mL.
ADVIA Centaur® Cortisol Master Curve Materials is an in vitro diagnostic product containing various levels of cortisol in lyophilized human plasma with sodium azide. Each set contains seven lyophilized levels (MCM1-7); with a reconstituted volume of 1.0 mL each. MCM1 contains no analyte. The COR MCMs assigned values are lot-specific of target values: 0.00, 1.00, 2.00, 6.00, 12.0, 30.0, and 80.0 µg/dL.

The provided text describes the acceptance criteria and supporting studies for two Master Curve Materials (MCMs): ADVIA Centaur Prolactin (PRL) MCM and ADVIA Centaur Cortisol (COR) MCM. These materials are intended for in vitro diagnostic use in verifying the calibration and reportable range of their respective assays.

Here's a breakdown of the requested information:

ADVIA Centaur Prolactin (PRL) Master Curve Material

1. Table of acceptance criteria and reported device performance:

2. Sample size used for the test set and the data provenance:

• Real Time/Shelf Life (unopened): Test PRL MCMs stored unopened. Tested at T=0, 12 months, and 30 months. The sample size for each time point is not explicitly stated in terms of number of individual units, but it's implied that multiple samples were tested to establish dose recovery.
• In-Use Open Vial (reconstituted): Reconstituted PRL MCMs, each level pooled, aliquotted, and stored at 2-8°C. Tested in 5 replicates per level at T=0, 7, 14, 21, 28, and 29 days. (10 levels * 5 replicates * 6 time points = 300 measurements total, minimum).
• On-Board Stability: Pooled aliquots of test PRL MCMs in sample cups. Measured at T=0, 2, 4, and 5 hours. Sample size not explicitly stated for number of individual units, but likely multiple measurements per time point.
• Value Assignment Test Set: For a new PRL MCM lot, MCM1 is run in 5 replicates on two separate runs. MCM2-MCM10 were tested on 20 replicates in total (one run and four sample cups run in 5 replicates). Performance verification run used 6 replicates of each MCM level.
• Data Provenance: The studies were conducted by Siemens Healthcare Diagnostics, Inc. The data is retrospective for the purpose of demonstrating the device's performance for this 510(k) submission. Country of origin not explicitly stated, but the manufacturer is based in the USA.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
Not applicable. These are in vitro diagnostic materials used for calibration verification, not for making clinical diagnoses based on subjective expert review. The "ground truth" for the MCMs is established by their formulation (analyte-free for MCM1, spiked levels for others) and traceability to recognized standards (WHO 3rd IRP for Prolactin 84/500) and internal reference materials.

4. Adjudication method for the test set:
Not applicable for this type of device and study. Performance is assessed against quantitative, pre-defined acceptance criteria, not through expert adjudication of results.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
Not applicable. This is an in vitro diagnostic (IVD) material, not an AI-powered diagnostic device, and therefore no MRMC study was performed.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:
Not applicable. This is an IVD material, not an algorithm. Its performance is evaluated intrinsically through stability and value assignment studies on an automated analyzer (ADVIA Centaur system).

7. The type of ground truth used:
The ground truth for the PRL MCMs is primarily based on:

• Traceability to International Standards: Specifically, the World Health Organization (WHO) 3rd International Reference Preparation (IRP) for human Prolactin 84/500.
• Analytical Procedures: MCMs are manufactured using qualified materials and measurement procedures, and for MCMs 2-10, known concentrations of prolactin are spiked into a matrix. MCM1 is analyte-free basepool.
• Value Assignment: Reference calibrators are prepared using Prolactin stock traceable to the WHO standard. The MCMs are value assigned against these reference calibrators using a nested testing run protocol to account for system and run variation.

8. The sample size for the training set:
Not applicable. This is an IVD material, not an AI model that requires a training set.

9. How the ground truth for the training set was established:
Not applicable.

ADVIA Centaur Cortisol (COR) Master Curve Material

1. Table of acceptance criteria and reported device performance:

2. Sample size used for the test set and the data provenance:

• Real Time/Shelf Life (unopened): Test COR MCMs stored unopened. Tested at T=0, 12 months, 18 months, and 23 months. The sample size for each time point is not explicitly stated in terms of number of individual units, but it's implied that multiple samples were tested to establish dose recovery.
• In-Use Open Vial (reconstituted): Reconstituted COR MCMs, each level pooled, aliquotted, and stored at 2-8°C. Tested in 5 replicates per level at T=0, 2, 4, 7, 11, 14, and 15 days. (7 levels * 5 replicates * 7 time points = 245 measurements total, minimum).
• On-Board Stability: Pooled aliquots of test COR MCMs in sample cups. Measured at T=0, 2, 4, and 5 hours. Sample size not explicitly stated for number of individual units, but likely multiple measurements per time point.
• Value Assignment Test Set: For a new COR MCM lot, MCM1 is run in 5 replicates on two separate runs. MCM2-MCM7 were tested on 20 replicates in total (one run and four sample cups run in 5 replicates). Performance verification run used 6 replicates of each MCM level.
• Data Provenance: The studies were conducted by Siemens Healthcare Diagnostics, Inc. The data is retrospective for the purpose of demonstrating the device's performance for this 510(k) submission. Country of origin not explicitly stated, but the manufacturer is based in the USA.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
Not applicable. These are in vitro diagnostic materials used for calibration verification, not for making clinical diagnoses based on subjective expert review. The "ground truth" for the MCMs is established by their formulation (analyte-free for MCM1, spiked levels for others) and traceability to recognized standards (GCMS) and internal reference materials.

4. Adjudication method for the test set:
Not applicable for this type of device and study. Performance is assessed against quantitative, pre-defined acceptance criteria, not through expert adjudication of results.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
Not applicable. This is an in vitro diagnostic (IVD) material, not an AI-powered diagnostic device, and therefore no MRMC study was performed.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:
Not applicable. This is an IVD material, not an algorithm. Its performance is evaluated intrinsically through stability and value assignment studies on an automated analyzer (ADVIA Centaur system).

7. The type of ground truth used:
The ground truth for the COR MCMs is primarily based on:

• Traceability to Reference Methods: Specifically, gas chromatography-mass spectroscopy (GCMS) through analytically prepared internal standards.
• Analytical Procedures: MCMs are manufactured using qualified materials and measurement procedures, and for MCMs 2-7, known concentrations of cortisol are spiked into a matrix. MCM1 is analyte-free basepool.
• Value Assignment: Reference calibrators are prepared using cortisol stock traceable to GCMS. The MCMs are value assigned against these reference calibrators using a nested testing run protocol to account for system and run variation.

8. The sample size for the training set:
Not applicable. This is an IVD material, not an AI model that requires a training set.

9. How the ground truth for the training set was established:
Not applicable.

Ask a specific question about this device

The ADVIA Centaur® C-peptide (CpS) Master Curve Material is for in vitro diagnostic use in the verification of calibration and reportable range of the ADVIA Centaur C-peptide assay.

The ADVIA Centaur® Insulin (IRI) Master Curve Material is for in vitro diagnostic use in the verification of calibration and reportable range of the ADVIA Centaur Insulin assay.

ADVIA Centaur® C-peptide Master Curve Material is an in vitro diagnostic product containing various levels of C-peptide spiked in citric acid buffer with casein and preservatives. Each set contains ten levels (MCM1–10); ready-to-use 1.0 mL per level. MCM1 contains no analyte. The MCMs assigned values are lot-specific of target values 0.0 0.14, 0.25, 0.55, 1.05, 2.05, 4.00, 8.00, 16.0, 32.5 ng/mL.

ADVIA Centaur® Insulin Master Curve Materials is an in vitro diagnostic product containing various levels of insulin in buffered saline with casein, potassium thiocyanate (3.89%), sodium azide (

The provided document describes the Siemens ADVIA Centaur C-peptide (CpS) Master Curve Material (MCM) and ADVIA Centaur Insulin (IRI) Master Curve Material (MCM). These devices are described as in vitro diagnostic products for the verification of calibration and reportable range of their respective assays. The document focuses on establishing substantial equivalence to predicate devices and describes relevant performance characteristics, primarily stability and value assignment.

Here's an analysis of the acceptance criteria and supporting studies based on the provided text:

Device Type: In vitro diagnostic Master Curve Material (MCM) - these are control materials used to verify the calibration and reportable range of an assay, not a diagnostic device that produces patient-specific results. Therefore, the questions related to clinical performance (e.g., diagnostic accuracy metrics like sensitivity, specificity, PPV, NPV), multi-reader multi-case studies, human reader improvement with AI, and specific ground truth types like pathology or outcomes data are not applicable in the context of this device and the provided documentation. The "performance" here refers to the stability and accurate value assignment of the control material itself.

1. Acceptance Criteria and Reported Device Performance

For ADVIA Centaur C-peptide (CpS) Master Curve Material (MCM):

Ask a specific question about this device

The ADVIA Centaur® Vitamin B12 (VB12) Master Curve Material is for in the verification of calibration and reportable range of the ADVIA Centaur VB12 assay.

The ADVIA Centaur® Total hCG (ThCG) Master Curve Material is for in the verification of calibration and reportable range of the ADVIA Centaur ThCG assay.

The ADVIA Centaur® Testosterone (TSTO) Master Curve Material is for in the verification of calibration and reportable range of the ADVIA Centaur Testosterone assay.

ADVIA Centaur® Vitamin B12 Master Curve Material is an in vitro diagnostic product containing various levels of vitamin B12 in buffered human serum albumin with sodium azide (0.2%) and preservatives. Each set contains six levels (MCM1-6); with a fill volume of 1.0 mL per level. VB12 MCMs are ready-to-use liquid products. MCM1 contains no analyte. The MCMs assigned values are lot-specific of target values: 0.00, 100, 250, 500, 1000, and 2200 pg/mL.

ADVIA Centaur® ThCG Master Curve Materials is an in vitro diagnostic product containing various levels of ThCG in lyophilized equine serum with preservatives including amphotericin B. Each set contains ten lyophilized levels (MCM1-10); with a reconstituted volume of 1.0 mL each. MCM1 contains no analyte. The ThCG MCMs assigned values are lot specific of target values: 0.0, 5.00, 10.0, 25.0, 50.0, 100, 250, 500, 750, and 1400 mIU/mL.

ADVIA Centaur® TSTO Master Curve Materials is an in vitro diagnostic product containing various levels of testosterone spiked in lyophilized human plasma with sodium azide and preservatives. Each set contains seven lyophilized levels (MCM1-7); with a reconstituted volume of 1.0 mL each. MCMI contains no analyte. The TSTO MCMs assigned values are lot specific of target values 0.00, 50.0, 100, 500, 750, 1000, and 1600 ng/dL.

Acceptance Criteria and Study for ADVIA Centaur® VB12 Master Curve Material

The document describes three separate Master Curve Materials (MCMs): VB12, ThCG, and TSTO. This analysis focuses specifically on the ADVIA Centaur® Vitamin B12 (VB12) Master Curve Material.

1. Table of Acceptance Criteria and Reported Device Performance

The acceptance criteria for the ADVIA Centaur® VB12 MCMs primarily relate to their stability. The study demonstrated that the device met these criteria.

• MCM2: % dose recovery within 75% to 125%
• MCM3-6: % dose recovery within 85% to 115%
  (All calculated back to Day 0 and/or no adverse trends) | Met acceptance criteria up to the 15 months' time point, supporting a shelf-life claim of 14 months. Unopened storage shelf-life is indicated by the expiration date on the vial label. |
  | On-Board Stability | - MCM1: Dose recovery ≤ 45 pg/mL
• MCM2: % dose recovery within 75% to 125%
• MCM3-6: % dose recovery within 85% to 115%
  (All calculated to T=0) | Met acceptance criteria up to 5 hours, supporting an on-board stability claim of 4 hours. |

2. Sample Size Used for the Test Set and Data Provenance

• Test Set Description: The test set for stability studies consisted of "Test VB12 MCMs" which were individual levels of the Master Curve Material (MCM1-6).
• Sample Size:
  • Real Time/Shelf Life: Not explicitly stated as a number of individual samples, but likely involved multiple aliquots of each MCM level (MCM1-6) stored and tested at T=0, 6 months, 12 months, and 15 months. The exact number of replicates per time point is not specified but implied to be sufficient for a robust assessment.
  • On-Board Stability: Not explicitly stated as a number of individual samples, but "Pooled aliquots of test VB12 MCMs in sample cups" were used and measured at T=0, 2, 4, and 5 hours. The exact number of replicates per time point is not specified.
• Data Provenance: Not explicitly stated in the provided text (e.g., country of origin). The studies appear to be prospective as they involved controlled storage and testing over defined time intervals to assess stability.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

This device is a Quality Control (QC) material, not a diagnostic device requiring human interpretation of clinical images or data. Therefore, the concept of "experts" establishing ground truth in the traditional sense (e.g., radiologists) does not apply. The "ground truth" for the performance of this QC material is established by analytical testing against defined reference materials and specifications.

4. Adjudication Method for the Test Set

The concept of an adjudication method (like 2+1, 3+1) is not applicable here. The performance is assessed by comparing dose recovery results to pre-defined numerical acceptance criteria for stability.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

No, an MRMC comparative effectiveness study was not done. This type of study is relevant for diagnostic devices where human readers interpret clinical cases, often with and without AI assistance. This device is a quality control material for an in-vitro diagnostic assay.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

The performance study (stability) is inherently "standalone" in the sense that it evaluates the material's integrity over time without human-in-the-loop performance, as it's a quality control product. The assay itself for which this MCM is used is automated.

7. The Type of Ground Truth Used

The ground truth for the VB12 MCM is established through:

• Traceability to a recognized standard: The assigned reference calibrators are prepared using USP (United States Pharmacopeia) VB12 stock and are traceable to USP internal material.
• Defined analytical specifications: The dose recovery acceptance criteria (e.g., ≤ 45 pg/mL, % recovery ranges) serve as the "ground truth" for determining if the material remains stable and performs as expected.
• Manufacturing procedures: MCMs are manufactured using "qualified materials and measurement procedures."

8. The Sample Size for the Training Set

This device is a physical Master Curve Material (MCM), not a machine learning model that requires a "training set" in the conventional sense. The "value assignment" process could be considered analogous to establishing its baseline characteristics.

For value assignment of a new VB12 MCM lot:

• MCM1: Run in 5 replicates on two separate runs using one reagent kit lot.
• MCM2-MCM6: Tested on 20 replicates in total, comprised of one run and four sample cups run in 5 replicates on one system and one reagent kit lot.

9. How the Ground Truth for the Training Set Was Established

As noted above, there isn't a "training set" in the machine learning context. However, the process by which the "ground truth" or assigned values for the MCMs are established is described as follows:

• Reference Calibrators: The ADVIA Centaur VB12 MCMs are value assigned using assigned reference calibrators. These calibrators are prepared using USP (United States Pharmacopeia) VB12 stock and are traceable to USP internal material.
• Value Assignment Process:
  • MCM1's target is 0.0 dose, and its quality control specifications ensure it measures at or below the assay sensitivity limit.
  • A nested testing run protocol is used for MCM2-MCM6, involving running alternating samples of the reference and new MCM level in the same run to remove system and run variation.
  • Resulting MCM dose values are generated using a two-point calibration.
  • The new MCM dose is calculated based on the relationship between the observed reference MCM dose and its assigned value.
• Performance Verification: A performance verification run with 6 replicates of each MCM level (using one instrument, one reagent kit lot, and Bio-Rad controls) is conducted. The mean MCM doses of the new lot must fall within customer range specifications.

Ask a specific question about this device

The ADVIA Centaur® TnI-Ultra® Master Curve Material is for in vitro diagnostic use in the verification of calibration and reportable range of the ADVIA Centaur TnI-Ultra assay.
The ADVIA Centaur® Digoxin Master Curve Material is for in vitro diagnostic use in the verification of calibration and reportable range of the ADVIA Centaur Digoxin assay.

ADVIA Centaur® TnI-Ultra® Master Curve Material is an in vitro diagnostic product containing various levels of bovine cardiac troponin I in a goat serum matrix with preservatives. Each set contains five lyophilized levels (MCM1-5); with a reconstituted volume of 1.0 ml each. MCM1 contains no analyte. The Tnl-Ultra MCMs assigned values are lot-specific of target values 0.00, 1.00, 3.50, 14.0 and 40.0 ng/mL.
ADVIA Centaur® Digoxin Master Curve Materials is an in vitro diagnostic product containing various levels of digoxin in defibrinated human plasma with sodium azide (0.1% after reconstitution) and preservatives. Each set contains six lyophilized levels (MCM1-6); with a reconstituted volume of 1.0 mL each. MCM1 contains no analyte. The Digoxin MCMs assigned values are lot specific of target values 0.0, 0.50, 1.00, 2.00, 3.00, 5.50 ng/mL.

The provided text describes two separate devices: ADVIA Centaur® TnI-Ultra® Master Curve Material (MCM) and ADVIA Centaur® Digoxin Master Curve Material (MCM). Both are quality control materials. I will detail the acceptance criteria and study information for each device independently.

ADVIA Centaur® TnI-Ultra® Master Curve Material (MCM)

1. Table of Acceptance Criteria and Reported Device Performance

• MCM2-5: % dose recovery within 85% to 115% calculated to Day 0
• No adverse trends | Acceptance criteria were met up to the 10 months time point, supporting a shelf-life claim of 9 months. |
  | Stability: In Use (Open Vial) @ 2-8°C (Reconstituted) | - MCM1: Dose recovery ≤ 0.02 dose (versus freshly reconstituted -80°C stored MCM1 average dose)
• MCM2-5: % dose recovery within 85% to 115% (versus freshly reconstituted -80°C stored MCM2-5 average dose) | Acceptance criteria were met up to the 9 hour time point, supporting an open vial claim of 8 hours when stored at 2-8°C. |
  | Stability: In Use (Open Vial) @ -20°C (Reconstituted) | - MCM1: Dose recovery ≤ 0.02 dose (versus freshly reconstituted -80°C stored MCM1 average dose)
• MCM2-5: % dose recovery within 85% to 115% (versus freshly reconstituted -80°C stored MCM2-5 average dose) | Acceptance criteria were met up to the 63 days time point, supporting an open vial (reconstituted) claim stored at -20°C for 60 days. |
  | Stability: On-Board | - MCM1: Dose recovery

Ask a specific question about this device

For in vitro diagnostic use in the quantitative determination of free thyroxine (FTA) in serum or plasma (heparinized or EDTA), using the ADVIA Centaur and ADVIA Centaur XP systems. Measurements of free thyroxine are used in the diagnosis and treatment of thyroid disease.

For in vitro diagnostic use in the quantitative determination of thyroxine (T4) in serum using the ADVIA Centaur and ADVIA Centaur XP systems. Measurements of thyroxine are used in the diagnosis and treatment of thyroid disease.

Not Found

The provided 510(k) summary focuses on the addition of pediatric reference intervals to existing ADVIA Centaur FT4 and T4 assays, rather than the development of a new device or a comparative effectiveness study involving AI. Therefore, many of the requested elements for a study proving device meets acceptance criteria (such as MRMC, standalone performance, ground truth establishment for training, etc.) are not directly applicable or explicitly detailed in this document.

However, based on the information provided, here's a breakdown of the acceptance criteria and the study conducted for the pediatric reference intervals:

1. A table of acceptance criteria and the reported device performance

The "acceptance criteria" here are implicitly tied to the established pediatric reference intervals themselves, and the "reported device performance" is the statistical summary of the patient data used to derive these intervals. The document states that the previously established euthyroid adult reference intervals and analytical measuring ranges already apply. The acceptance criteria for the pediatric reference intervals specifically are:

• The established pediatric reference intervals must be either within or above the previously established euthyroid adult reference intervals.
• The established pediatric reference intervals must be within the analytical measuring ranges of the ADVIA Centaur FT4 and T4 assays.

As stated in the conclusions: "The newly-established pediatric reference intervals are either within or are above the previously-established reference intervals for euthyroid (normal thyroid) adult populations and they are within the analytical measuring ranges of the ADVIA Centaur FT4 and T4 assays." This confirms the device (when interpreted with these new intervals) meets its implicitly defined acceptance criteria.

2. Sample size used for the test set and the data provenance

• Sample Size: A total of 454 patients were analyzed: 72 infants, 190 children, and 129 adolescents.
• Data Provenance: Not explicitly stated, but typically reference interval studies use samples collected from healthy individuals within the specified age groups, often from multiple geographic locations to ensure generalizability. It's not specified if this was retrospective or prospective, though the term "analyzed" suggests it could have been retrospective analysis of collected samples.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

This information is not provided in the summary. For establishing reference intervals, the "ground truth" is typically defined by recruiting a statistically robust population of "healthy" or "euthyroid" individuals based on clinical criteria and medical examination, rather than expert consensus on individual cases. The document refers to CLSI C28-A3c, which is a guideline for establishing reference intervals. This guideline outlines methods for selecting reference individuals and statistical methods for calculating intervals, but not necessarily "experts" in the sense of adjudicating individual cases.

4. Adjudication method for the test set

This information is not provided and is generally not applicable to the establishment of reference intervals. The process involves clinical selection criteria for healthy individuals and statistical determination of intervals.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

Not applicable. This submission is for updating reference intervals for an existing IVD assay, not for an AI-based device or a comparative effectiveness study involving human readers or AI assistance.

6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done

The device is an in vitro diagnostic (IVD) assay, not an algorithm or AI. Its performance is inherent in its analytical capabilities, which were previously established and cross-referenced to earlier 510(k) submissions (K905532, K080167, K971418). The current submission states, "The inclusion of pediatric reference intervals in the Instructions for Use (Package Inserts) does not necessitate the collection of additional analytical performance data." Therefore, no new standalone performance study was conducted for this submission as the analytical performance was deemed sufficient by previous submissions.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

For this type of study (establishing reference intervals), the "ground truth" is typically an "apparently healthy" or "euthyroid" state for the pediatric population, as defined by rigorous clinical selection criteria (e.g., absence of diseases, medications, or conditions known to affect thyroid function) as per CLSI guidelines. The specific criteria are not detailed but are implied by the reference to CLSI C28-A3c.

8. The sample size for the training set

This study is focused on establishing reference intervals, which typically involves a single dataset used for derivation. There isn't a "training set" in the context of machine learning. The 454 patients (72 infants, 190 children, 129 adolescents) constitute the dataset used to establish these reference intervals.

9. How the ground truth for the training set was established

As noted in point 7, the "ground truth" for the individuals included in the study (which acts as the "training set" for interval derivation) would be their status as "apparently healthy" or "euthyroid" pediatric individuals. This status would have been established through a process of screening, clinical assessment, and potentially other diagnostic tests, following the methodologies outlined in the CLSI C28-A3c guideline mentioned in the submission. The specific clinical criteria used for selection are not provided in this summary.

Ask a specific question about this device